REL and neoplasm: Therefore, unlike the lymphoid immune checkpoint drugs such as PD-1 antibodies that directly target CD8+ T lymphocytes, the control of tumor growth and CD8+ T activity by c-Rel knockdown is more likely contributed by the diminished MDSC function and the resulting changes in the immune suppressive tumor microenvironment.